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Background: Agent-based models provide a formidable tool for exploring complex
and emergent behaviour of biological systems as well as accurate results but with the
drawback of needing a lot of computational power and time for subsequent analysis. On
the other hand, equation-based models can more easily be used for complex analysis
in a much shorter timescale. Methods & Objective: This paper formulates an
ordinary diﬀerential equations and stochastic diﬀerential equations model to capture
the behaviour of an existing agent-based model of tumour cell reprogramming and
applies it to optimization of possible treatment as well as dosage sensitivity analysis.
Results: For certain values of the parameter space a close match between the equation-
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based and agent-based models is achieved. The need for division of labour between the
two approaches is explored.
Keywords




The research concerns a particular cancer-related clinical setting. The basic research aim was
to formulate two diﬀerent types of continuum models, ordinary diﬀerential equations (ODE)
and stochastic diﬀerential equations (SDE), that could match the qualitative and quantitative
behaviour of an agent-based model (ABM) in that setting. Furthermore, connecting these
models parametrization-wise is not usually trivial but we will show the parametrization we
have done allows us to move from the agent-based to the continuum view for optimization
and sensitivity analysis. When a clinically relevant setting is considered then each model
has advantages and disadvantages. Speciﬁcally ABMs provide more realistic results which
can be used by both the researcher and the clinician but systematic and rigorous analysis of
the system simulated by the ABM is very time-consuming. Continuum models by contrast
allow for complex analysis and exploration of the underlying system with the trade-oﬀ of
realism and accuracy. Matching between the two types of models would mean that one
could use the continuum model for analysis, such as optimization and sensitivity analysis.
These procedures could be extremely time-consuming if performed directly in ABMs for two
reasons. The ﬁrst is that ABMs are in a way in-silico experiments which have to be run a
great number of times for each set of parameter values in order to be able to draw a sensible
conclusion. Moreover and speciﬁcally in the case of cell biology scenarios, realistic numbers
of cells in a system could reach the order of millions. Such numbers would mean that
huge computational power is needed to run simulations, in contrast to continuum equations
which usually can be handled numerically very fast. On the other hand, ABMs provide a
more realistic representation of the real system and can prove very valuable to clinicians.
Hence the main idea here is to move from an ABM to a continuum model for analysis and
understanding of the system and dynamics and then move back to the ABM in order to use
the conclusions of the analysis to obtain realistic data.
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Creating a rigorous connection between the two aforementioned types of models for a
generic system is a diﬃcult task, depending on the system under consideration. Therefore,
we approach our main idea on a case-by-case basis. To this end we reproduce the agent-based
model found in the recent paper by P.M. Biava et al.1 based on a recently developed tumour
paradigm which is supported experimentally. Attempts to connect agent-based models to
equation-based models in order for one of them to act as a complementary model to the
other have been done previously in a number of diﬀerent papers.24
1.2 Cancer cell model
Several experimental studies exploring the interaction between a tumour and the embryonic
micro-environment have shown a delay or even stopping of the proliferation of diﬀerent hu-
man cancer lines when development and more speciﬁcally organogenesis is at work5 . In 2002
the same group that developed the ABM model1 showed that factors taken from speciﬁc de-
velopmental stages of the zebraﬁsh embryo decreased the proliferation rate of several human
cancer lines signiﬁcantly.6 In addition to in-vitro, an in-vivo study revealed a slowdown of
the Lewis lung cancer carcinoma in mice when administered with developmental factors.7
Moreover, recent experimental results have demonstrated that embryonic and cancer cells
share some of the molecular signal and pathways.
The above has led to the development of a new tumour paradigm in which cancer is con-
sidered a developmental deviation of normal undiﬀerentiated cells.5 Cancer cells are viewed
as undiﬀerentiated cells that are stuck in the proliferative stage between two diﬀerentia-
tion stages. As a result the same molecular factors that diﬀerentiate cells during embryonic
development could help the cancer diﬀerentiate and even become a healthy cell. A less dif-
ferentiated stem cell diﬀers from a more diﬀerentiated one in the fact that a greater number
of genes are expressed in the latter and in reality all the developmental factors have to work
in a complete network to induce the expression of many genes.5 In this paradigm there are
ﬁve malignancy stages, from more to less malignant, in accordance with the ﬁve steps of
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a stem cell, i.e. pluripotent (most malignant), multipotent, oligopotent, diﬀerentiating and
diﬀerentiated (healthy).
1.3 Aims
The rest of our study is divided into four main sections and some into further subsections.
Section 2 is material and methods. Initially we present the ABM we developed which is
very similar in nature to the model developed in.1 We build on this model to explore dosage
optimization and sensitivity analysis. We explain how the model works, its agents as well
as the parameter values being derived from empirical and experimental data. Following the
development of the ABM we formulate two new models, an ordinary ODE and a SDE to
capture the dynamics of the ABM. We justify the form of our models and explain the ﬁtting
to the ABM procedure. Then, we extend the ODE to two more complex and realistic forms
that will be used for further analysis. Section 3 presents the results and discussion. Here
we show how well the two continuum models match the ABM and present the rest of the
analysis which is related to a hypothetical therapy based on the cancer cell theory. Namely,
we conduct an optimization of the dosage of molecular factors as well as an analysis of a
patient missing some dosages. Section 4 is the further discussion, where we summarize
our work and ﬁndings. Finally, in section 5, the conclusion, we raise possible issues and
areas left unexplored as well as further work towards making a more realistic agent-based
and continuum model.
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2 Material and methods
2.1 Agent-based model of cancer cell diﬀerentiation
2.1.1 Form of the agent-based model
Purpose. The purpose of the ABM is to simulate the temporal evolution of the total popu-
lation of ﬁve cancer-cells diﬀerentiation stages, going from most malignant to healthy cells,
induced by interaction with four distinct types of molecular factors, found in embryonic
development, each characteristic to the diﬀerentiation stage. This model could potentially
advise a clinician on the progress of the cancer treated by administration of these factors.
Grid cells, temporal and spatial scale. The world is a rectangular grid of discrete patches
and it is also toroidal, meaning that both the horizontal and vertical edges are wrapped.
Spatial units are abstract. Since we do not model volume-exclusion eﬀects there can be
many cells in the same patch; that can be interpreted as patches being large compared to
individual cells. The time units (time-steps) are minutes since the therapy time-frame is days
and hence smaller times would require a huge simulation time. Simulation occurs through
the passing of discrete time-steps.
Cancer cells. As mentioned before there are ﬁve cancer stages named after the respective
stem-cell stages in order of malignancy: pluripotent, multipotent, oligopotent, diﬀerentiating
and diﬀerentiated (healthy) cells. At each time step cells might grow according to a prob-
ability representing their growth rate and interact (or not), depending upon ﬁtness, with
factors in the same patch as the cells. To account for the fact that cancer cells are relatively
static and diﬀuse much slower than factors (1000 times slower1), each cancer cell moves by
a unit one (jumping to one of the 8 neighbour patches) every 1000 time-steps.
Molecular factors. There are four types of factors each representing a diﬀerent diﬀer-
entiation stage and aﬀecting the corresponding cancer diﬀerentiation stage. There are no
factors for healthy cells. At every time-step factors move a distance of one (one of the eight
neighbour patches) and interact with cells according to their ﬁtness, which is characteristic
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of the stage.
Dosage. Doses of factors are administered every 8 hours (480 minutes). Every dose
includes 2000 factors of each type which are randomly distributed in the ABM world. This
dosage strategy is chosen as a simplistic way of killing all malignant cancer cells.
Growth. At each time step each cell has a probability of dividing into two daughters.
The probability is given by the growth rate per minute of that diﬀerentiation stage of cancer
derived from empirical data. Daughters are cancer cells of the same stage. We are not
interested in the dynamics of the healthy population and hence the growth rate is kept at
zero.
Interaction. If a factor and a cell are in the same patch they might interact with some
probability called ﬁtness. Fitness is a 4x4 matrix since factors could potentially interact with
all diﬀerent malignant cancer stages but both in the original ABM and here we consider
a diagonal matrix where each type of factor only interacts with cancer cells of the same
diﬀerentiation-stage type. If a factor interacts with a cell then that factor dies and the cell
moves to the next diﬀerentiation stage.
Initialization. The model is initialized with 1000 randomly distributed pluripotent cancer
cells and zero for the other four populations and 2000 factors of every type.
2.1.2 Parameters
Fitness values were taken from the original ABM paper1 where they were derived by ﬁtting
the simulation to experimental data from.6 We derived growth rates for each stage by ﬁt-
ting exponentials to the proliferation curves of kidney adenocarcinoma cells found in6 The
growth rates used in the original ABM might have been found by ﬁtting to diﬀerent cancer
proliferation curves from the same paper as there were many cancer lines and there was no
mention as to the speciﬁc ones used. The coeﬃcients of the exponentials correspond to the
growth rates for each cancer stage and are used for all three model types as we will see.
Tables 1,2 show the values for both the ﬁtness and growth rates. Despite not knowing some
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speciﬁcs of the ABM in1 like the world dimensions, movement proﬁles of agents and exact
growth rates ﬁtted and used we tried to reproduce the two plots of Fig3. shown in1 for the
two dosing strategies mentioned in that paper. The plots can be seen in the appendix.
Table 1: Fitness of molecular factors.
Stage I factors Stage II factors Stage III factors Stage IV factors
Pluripotent 4% 0 0 0
Multipotent 0 5% 0 0
Oligopotent 0 0 2.5% 0
Diﬀerentiating 0 0 0 1%
Table 2: Growth rates of cancer stages.
Stage Pluripotent Multipotent Oligopotent Diﬀerentiating Healthy
Growth rate (min−1) 3.9 ∗ 10−4 3.3 ∗ 10−4 3.1 ∗ 10−4 2.8 ∗ 10−4 0
Figure 1 shows a stopped frame of a random run of the ABM after a few thousand
time-steps with the parameter values given in the aforementioned tables.
Figure 1: Single frame of a random run of the ABM with the parameter values found in
table 1 and 2.
8
2.2 Deterministic continuum model
Despite the fact that the ABM provides a more realistic representation of the real system,
performing complex analysis and optimization can prove extremely time-consuming as results
may need to be obtained by running the model several times with many parameter values.
Formulating and solving numerically a continuum model that matches the ABM allows that
analysis to be done much faster and more rigorously. We do not need the continuum model
to match every aspect of the ABM, only the parameter/behaviour space that is of interest.
As mentioned before, in1 an ABM was formulated to represent the biological system
without any continuum analog. Here, we describe an ordinary diﬀerential equations system
(ODE) to capture the main dynamics of our ABM. The ODE has the form of coupled
equations, identical to chemical reaction kinetics with the addition of growth. This means
that the interaction of cells and factors is proportional to their concentration. This choice
is justiﬁed by the form of the ABM where no exclusion phenomena are considered and cells
and factors are positioned randomly in the whole space, giving an almost homogeneous mix.
In this ODE system each variable represents one of the ﬁve cell and four factor populations
represented by the initial letter of the type of cell or factor, e.g. P for pluripotent cells and
Fp for the factors. The model equations are given below:
P˙ (t) = gpP (t)− βP (t)Fp(t)f1, (1a)
M˙(t) = gmM(t)− βM(t)Fm(t)f2 + βP (t)Fp(t)f1, (1b)
O˙(t) = goO(t)− βO(t)Fo(t)f3 + βM(t)Fm(t)f2, (1c)
D˙(t) = gdD(t)− βD(t)Fd(t)f4 + βO(t)Fo(t)f3, (1d)
H˙(t) = ghH(t) + βD(t)Fd(t)f4, (1e)
F˙p(t) = Ds− βP (t)Fp(t)f1, (2a)
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F˙m(t) = Ds− βM(t)Fm(t)f2, (2b)
F˙o(t) = Ds− βO(t)Fo(t)f3, (2c)
F˙d(t) = Ds− βD(t)Fd(t)f4. (2d)
Here gi represents the growth rates of diﬀerent cancer cell stages, where i = {p,m, o, d, h},
and fj is the ﬁtness, where j = {1, 2, 3, 4}. The values for these parameters are exactly the
same as the ABM and are given by Tables 1 and Table 2 respectively. Ds is the dosage.
In the ODE the dosage is modelled by constant value, instead of discrete steps. The value
is given by the size multiplied by the frequency. Hence,
Ds = Size ∗ f = 2000/480 = 4.1666factors ∗min−1.
Moreover, it should be noted that the interaction term, i.e. β[CancerCells][Factors] is
the same in both the cancer cell equations and the respective factor equations. This can be
understood again by taking as an example chemical reactions. A typical reaction has the
form:
a[A] + b[B]→ c[C]













. In our case since one cell interacts with one factor to produce one
diﬀerent type of cell we have a = b = c = 1 hence the reaction rate, given by the reaction
term, is the same for both cells and factors.
In the ODE system there is an extra parameter, β, which is the rate of interaction per
cell per minute. This parameter is the same for all interaction terms since it is dependent on
external conditions such as the size of the world or the diﬀusive speed of the cells and factors.
It is the most important parameter since it is the one that needs to be calibrated in order for
the two models to match. Its calibration is conducted by the use of the NonLinearModelFit
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function found in Mathematica. To produce the data set the ABM was run 100 times with
the same parameter values and a total time of 8000 minutes which allowed for all malignant
cells to die out. Then, the 100 runs were averaged to give mean population evolution curves
for each cell population.
Following calibration, the ODE model will work as a stepping stone for more complex
models that will be used for our analysis. It is worth mentioning that β is the only ﬁttable
parameter as the growth parameters for all our models are found from ﬁtting exponential
to cancer proliferation curves and hence there is no doubt as to which model parameter
corresponds to which experimental parameter.
2.3 Stochastic continuum model
In addition to the deterministic ODE model used to describe the agent-based model, a
stochastic diﬀerential equations (SDE) model was also formulated. Here we compare it to
the deterministic model as well as the ABM.
The SDE model is of the Langevin kind and its derivation as well as justiﬁcation can
be found in.8 In Appendix A we include the basic theory behind the derivation as well as
the case-speciﬁc values that are used to create our model. The equations for the cancer cell
populations are:































Here, both population variables (P,M,O,D,H) and Gaussian white (Γ1-Gamma13) noise
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are time-dependent see Appendix A, e.g. P means P (t).
The numerical simulation of the SDE model was conducted with Mathematica, using the
Euler-Maruyama method found in.9
2.4 Extension of the ODE model
After calibration of our initial ODE system with the ABM, it can be used as a cornerstone
to build more complex models that can be used for further analysis of the system of interest.
Speciﬁcally, two new models were created, both being diﬀerent from the ﬁrst in the dosage
term and in the fact that factors die out. The latter comes from the fact that an administered
drug is metabolised by the organism and after the passing of a few hours its quantity drops
exponentially. This provides a much more realistic system for clinically relevant analysis
since otherwise a single dose can last for many days or even weeks until all factor molecules
have interacted with the cancer. So in both of the following models the factors decay with
a rate of 90% decrease in 8 hours. The ODE for the factor population becomes:
F˙i(t) = dosage− βFi(t)Ci(t)− γFi(t)
where C is the respective cancer population and γ is the decay rate of factors due to
metabolism with a value of 4.8 ∗ 10−3min−1.
2.4.1 Step doses
In the initial model the dosage is constant and all four doses are administered from the
beginning of the simulation and are also given even after the extinction of the respective
cancer stage. This scenario is unsuitable for clinical analysis; hence a new model was created
where the doses were given in a step-like manner, meaning that the dosing of a factor type
starts after the creation of the respective cancer type and stops immediately after extinction.
This is achieved by multiplying the initial dose term, Ds, by an inverse tangent function as
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this gives a smooth transition from zero to Ds. The function has the following form:
dosage = Ds ∗ arctan(100 ∗ C) 2
pi
where C represents a cancer cell population. When C goes to zero the dosage goes to zero
and when C goes above zero the function increases rapidly to a steady value which is given
by Ds. The coeﬃcient of 100 is used to make the increase or decrease faster.
Now this model is used in order to explore how the time of complete cancer extinction is
aﬀected by the increase of the dosing and what is the best distribution of the total dosage for
the four diﬀerent doses. That is to provide insight as to the importance of each of the four
factors. The time of cancer extinction is speciﬁed as the time when all numerical solutions
for the four malignant cancer populations go below 1. As in the ABM the initial condition
for the ﬁrst factor population is 2000 but zero for the rest and 1000 for the pluripotent cancer
cells and zero for the other populations.
2.4.2 δ function doses
In the second additional model doses are administered in a way similar to the ABM, in the
form of an injection. Here, doses are given in full every 8 hours. To achieve this we used a
sum of Dirac delta functions multiplied by the size of the dose (the total factor count). The
dosage function is as follows:
dosage = Size ∗
n−1∑
i=1
αiδ(t− i ∗ 480).
Here, n is the total number of dosages depending on the number of days of the treatment
and αi is the intake coeﬃcient which takes the value of zero or one depending on whether a
particular dose was taken or missed by the patient. The ﬁrst dose is taken at time zero and
it is given as initial conditions for the factors-population ODE. That allows for a sensitivity
analysis of missed doses, concerning how the time of cancer extinction is aﬀected by a missed
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dose as well as the importance of the dose timing.
3 Results and Discussion
3.1 Fitting of ABM and ODE and comparison with SDE
Using NonLinearModelFit we found that the β which gives the best match between the ABM
and the initial ODE has the value 6.857 ∗ 10−6agent−1min−1. Figure 2 shows the variation
of the populations for 100 runs of the ABM model. We can see that there are no unexpected
behaviours and that for these parameters values a mean approximation should work well.
For subsequent analysis the value was rounded to 6.9∗10−6agent−1min−1. The value as well
as the basic statistics for β-value ﬁtting are:
Estimate Standard Error t-Statistic P-Value
β 6.85734 ∗ 10−6 1.44617 ∗ 10−9 4741.74 1.63450391131 ∗ 10−55019
We can see the variation of the 100 ABM runs in Figure 2.
Figure 2: Variation of the 100 ABM runs for the parameter values found in Table 1.
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Figure 3 demonstrates the comparison of the ODE and the mean ABM proliferation
curves.
Figure 3: Comparison of the average of 100 runs of the ABM, with the parameter values
found in Table 1 and 2, and of the ODE with the same values for the growth rates and
dosage and a β = 6.9 ∗ 10−6agent−1min−1 . The dashed lines are the populations of the
ODE model and the full lines are for the ABM.
The match of the two models for the speciﬁc, experimentally obtained, parameter values
is very close. There is both a qualitative and quantitative matching between the two which
hints towards using the continuum model for further analysis by extending it as mentioned
in the previous section.
Using the same β we plot the average of 50 SDE runs against the same 100-runs average
of the ABM, as used in the ODE ﬁtting; this gives us again a very good ﬁtting between the
two models. The behaviour of the SDE is almost indistinguishable from that of the ODE
for these parameter values. Figure 4 shows the comparison between the SDE and ABM.
Finally, Figure 5 shows the range of variation for the ﬁve populations for these 50 runs.
The healthy cell population shows a larger variation but this can be accounted for by the
variation of the diﬀerentiating cancer cell population especially close to the turning point.
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Figure 4: Comparison of the average of 100 runs of the ABM, with the parameter values
found in Table 1 and 2, and of the SDE with the same values for the growth rates and dosage
and a β = 6.9 ∗ 10−6agent−1min−1 . The dashed lines are the populations of the SDE model
and the full lines are for the ABM.
Figure 5: Range of variation of 50 runs for the ﬁve types of cells for the SDE model.
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So small variation throughout the simulation can lead to signiﬁcant diﬀerences in the total
amount of cells (healthy population) but without any other consequences. Due to the small
variations observed in both the ABM and the SDE for the parameter values used we conclude
that the dynamics of the system can be well approximated by a mean ﬁeld approach hence
we will use the ODE for the subsequent analysis.
3.2 Dosage optimization
Using the ﬁrst of the additional models (step-like dosage) we can optimize the treatment by
administrating diﬀerent doses for the four factors (scheme 1) and compare the results with
the scheme where doses are the same (scheme 2).
3.2.1 Optimal distributions
To ﬁnd the optimal distribution of the doses we ﬁrst pick a total dosage, meaning the sum of
the individual doses (Ds = Ds1 +Ds2 +Ds3 +Ds4), then we produce all the combinations
of four integer numbers that add up to D and from these we pick the one that gives the
shortest time of cancer extinction (ToCE). This procedure is repeated a number of times
for other total dosage values. The results are summed up in Table 3 and are illustrated in
Figure 5.
Table 3: Optimal distribution of doses for a ﬁxed total dosage.
Total dosage Stage I dose Stage II dose Stage III dose Stage IV dose ToCE (mins)
60 10 8 13 29 107280
70 11 9 16 34 64800
80 13 10 18 39 46368
90 14 12 20 44 36144
100 16 13 22 49 29520
110 18 14 24 54 25056
120 19 16 27 58 21600
Looking at the values we can see a pattern in how the dosage is distributed every time
we add an extra 10. More speciﬁcally almost every time 5 goes to the last dosage, except
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when going from 110 to 120 where the increase is by 4. So we have 40− 50% going to Ds4.
We also have 20 − 30% going to Ds3 and the rest 20 − 30% distributed at Ds1 and Ds2.
There was no case where we had 40% going to the ﬁrst two doses. From Table 3 we can see
that the last dose is the most important in aﬀecting time of cancer extinction by far followed
by the third dose, but then we see a turnover where the ﬁrst dose is more important than
the second. That order is evident in all total dosage values we selected.
To further explore this pattern of distribution we wanted to see whether it is present if
we move to the second and third best distributions. Tables 4 and 5 show the second and
third best combinations respectively along with the mins of cancer extinction for each.
Table 4: Second optimal distribution of doses for a ﬁxed total dosage.
Total dosage Stage I dose Stage II dose Stage III dose Stage IV dose ToCE (mins)
60 10 7 13 30 108144
70 12 9 15 34 64800
80 13 11 17 39 46656
90 15 12 20 43 36144
100 17 13 22 48 29664
110 18 15 24 53 25056
120 19 16 26 59 21600
Table 5: Third optimal distribution of doses for a ﬁxed total dosage.
Total dosage Stage I dose Stage II dose Stage III dose Stage IV dose ToCE (mins)
60 10 7 14 29 109440
70 11 9 15 35 64944
80 13 10 17 40 46656
90 15 11 20 44 36288
100 16 13 23 48 29664
110 18 14 25 53 25056
120 20 16 26 58 21600
The ﬁrst point we notice is that the ToCE is very slightly diﬀerent between optimal
distributions, one to three. The diﬀerence is only signiﬁcant in the smallest total dosage
(60). Moreover, we can see again the same ordering as well as overall pattern. Again, the
highest amount of dosing goes to Ds4 then Ds3 then Ds1 and ﬁnally Ds2. When extra
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dosage is provided again the most of it goes to Ds4, this time 40− 60%. 20− 30% goes to
Ds3 and 10−20% to Ds1, Ds2 individually. So, the overall pattern is preserved. That gives
an indication indeed of how a clinician could distribute not only their initial total dosage
but also any extra they administer.
To explore how changes in β might aﬀect the pattern of optimal dosage we performed
the same optimization for β′ = 2β and β′′ = β/2. Other than changes in the time of cancer
extinction and the total dosage needed, the patterns seemed to remain almost exactly the
same with again the greatest dosage given on the last does followed by the third, ﬁrst and
second.
Table 6: Optimal distribution of doses for a ﬁxed total dosage and β′ = 0.000014.
Total dosage Stage I dose Stage II dose Stage III dose Stage IV dose ToCE (mins)
60 10 8 13 29 21225
70 11 9 16 34 16708
80 12 11 18 39 13785
Table 7: Optimal distribution of doses for a ﬁxed total dosage and β′′ = 0.00000345.
Total dosage Stage I dose Stage II dose Stage III dose Stage IV dose ToCE (mins)
140 23 18 31 68 63666
150 25 19 33 73 53496
160 12 11 18 39 13785
3.2.2 Comparison to Scheme 2
Furthermore, we compare the optimal distribution to a scheme where all four dose values
are the same (total dosage divided by 4), for the same total dosage. These values are the
square markers of Figure 6. There are only three points as for the total dosage values of 90,
80, 70 and 60 the cancer survived. In addition we can see a very big diﬀerence in the ToCE,
pointing towards the eﬃciency of the optimal distribution.
Finally, in scheme 1 we can see that increasing the total dosage results in a plateau after
some value, meaning that the further you increase the total dosage the less beneﬁt you get.
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Figure 6: Total dosage versus time of cancer extinction for the optimal distribution of doses.
This needs to be taken into consideration for choosing the appropriate dosage by considering
both the ToCE as well as cost of dosing or side eﬀects.
3.3 Missing doses sensitivity analysis
Using the discrete dosing model we can explore what happens when a patient misses some
doses and how the results are aﬀected by the timing of those doses. To do that we ﬁrst
need to pick speciﬁc dosage size values for the four doses as well as the number of days for
administration. We can make an informed decision using our previous analysis. Table 3
shows that for a total dosage/frequency ratio of 120 cancer dies out at 21613 mins or 15
days. To make sure that the cancer is dead a clinician would probably need to add one
more day and not stop administration of drug at the exact time predicted here. Further-
more, this optimum result is achieved by distributing the dosage/frequency ratio in the four
doses as {19, 16, 27, 58}. That gives size values of {9120, 7680, 12960, 27840} for the four
doses respectively with a ﬁxed frequency of 8 hours. Again this number is rounded up to
{10000, 8000, 13000, 28000}. The error between the rounded up and the exact values is less
than 10% in all cases. That accuracy error is consistent with the measurement accuracy of
the concentration of complex biologial drugs (e.g. monoclonal antibodies). Hence a clinicial
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could potentialy increase the actual dosage to make sure that even with the error diﬀerence
the doses remain close to the exact values.
In Figure 7 we see the results of missing one dose. Here 16 days correspond to 48 doses
and we explore the eﬀect of missing either of them. We observe that the later the missing
dose is, the better it is for the patient but the diﬀerences are small and there is no danger
of the cancer surviving. The continuous line is the ToCE when all doses are administered.
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Figure 7: Time of cancer extinction with respect to the position of one missed dose. The
red line is the ToCE when all 48 doses are taken normally.
Also interesting is the contour plot of two missed doses. In that case we see that there
is a region where if two doses are lost then cancer survives. This is the white region of
Figure 8 above the dotted line, which shows how the plot should normally be. Figure 9 is
the complete plot whereas in Figure 8 we have zoomed to the interesting area. Here we still
see that the best case scenario is when doses are missed close to the end of the treatment
period, which is as expected. There is a large region where the position of the missed doses
does not aﬀect ToCE signiﬁcantly (orange contour). But as we move missed doses one or
two close to the end we can see sudden jumps to other contours of smaller ToCE. Finally,
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the blank region above the dotted line shows all the possible combinations of the two missed
doses. This sensitivity analysis can be potentially very useful in order to either warn the
patient or possibly increase the duration of the treatment period such that there is no blank
region at least for two doses. For example adding one more day (3 doses) gives us a contour
plot showing no cancer-surviving region (Figure 9).
Figure 8: Contour plot of ToCE versus the position of two missed doses for 23040 mins
or 16 days of treatment. White region above the dotted line indicates region where cancer
survives. (Cropped)
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Figure 9: Contour plot of ToCE versus the position of two missed doses for 23040 mins or
16 days of treatment.(full)
4 Further discussion
A crucial parameter to the ABM is the diﬀusivity, i.e. how fast factors and cancer cells diﬀuse
which in our captured in the ABM by the how often and how far agents move. According
to1 due to their size diﬀerence factors and cells must have a diﬀusion speed diﬀerence of the
order of 1000, meaning that the factors diﬀuse 1000 times faster than cells. Of course that
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Figure 10: Contour plot of ToCE versus the position of two missed doses for 24480 mins or
17 days of treatment.
is a relative diﬀerence and the actual speed in the ABM aﬀects the results signiﬁcantly, as
discussed below.
We initially tried the following scenario. Cells have unit speed, meaning that they move
randomly to one of their neighbour patches at each unit of time and factors can move 1-1000
units of distance (patches). At each time step a random integer number between 1-1000 is
chosen for the distance covered by factors. There are two issues with this scenario. The ﬁrst
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is that factors simply jump that distance without having the chance to interact with cell
in between. This is not realistic but necessary as otherwise the computational time needed
just for a single time step would be large. In addition this scenario appears, for our world
dimensions, well-mixed (factors and cells are everywhere). Although that gives a better
match with our ODE, which is expected since chemical-kinetics equations are mainly used
for well-mixed cases of chemicals, it is unrealistic for a cancer case especially since cancer is
more static.
The second scenario we tried, and the one we ﬁnally used, is that factors move a distance
1 every time-step and cancer cells move 1 every 1000 time steps. This has the following
advantages: a) factors can now interact in every time-step, b) the cancer is much more
static and grows out of its initialization positions. That scenario also gives rise to a diﬀerent
phenomenon. Since factors move slower and cancer cells are almost static there appears to be
a critical over-density phenomenon, meaning that if the cancer cell in a single location exceeds
a certain number then factors cannot kill them and that local population keeps increasing. In
the cases were the over-density mentioned above appears in the ABM we wanted to see if the
ODE can capture that behaviour to that end we tried changing the value for β which gave
a qualitative behaviour similar to the ABM but not a close quantitative match. That eﬀect
cannot be captured correctly by the ODE model since the parameter β, although dependent
on the agent speeds, cannot capture the full dynamics introduced by diﬀusion which would
require a spatial model. Despite the mismatch in that particular case if the malignant cancer
dies out completely then the two models match well, meaning that if the parameters are such
that the over-density is never achieved we can see a good ﬁt and that is the case for which
we ﬁtted β and performed the subsequent analysis. For the growth values found in Table
1 and an administration of 2000 factors every 8 hours the over-density never occurred and
hence cancer never survived (Figure 2), all malignant cancer died and the two models have
both a qualitative and quantitative match as we saw in Figure 3. That justiﬁes the use of an
ODE model. For diﬀerent parameter values and more general exploration there is probably
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the need for an alternative model of the form of a PDE in order to capture spatial eﬀects
as well. Moreover, if exclusion eﬀects are included then some of the over-densities can be
averted as cancer would be unable to grow without space.
From the above it is clear that the ODE cannot capture the ABM in its entirety, nor
does it need to since we do not need a full description of the ABM via an ODE: achieving
that would be very hard due to the diﬀerent nature of these models. We only need them
to be complementary and the continuum model to capture just the features and parameter
spaces we are interested in further exploring.4
1000 cells were selected for the simulation of the ABM. An increase or decrease of this
number would not have signiﬁcant eﬀects to the analysis performed, other than changes
in the total dosage, as long as we remain in the "well-mixed" regime were the chemical
kinetics-like ODE captures well. So as long as we avoid very small number of cells which in
the ABM and SDE can lead to unexpected extinction or very large number which can cause
the overdensity mentioned above the analysis holds.
The most important parameter in our continuous ODE model is β. It is a parameter
not controlled by the experimentalist/modeller that reﬂects some intrinsic properties of the
environment (size) and of the agents (speed, reaction type) and needs to be calibrated
according to the available data. Changes in that parameter reﬂect how often cells and
factors meet and hence have a change of interaction. As a result, an increase in β would
keep the qualitative behaviour the same as the one explored and the only diﬀerence would
be shorter timescales due to the fact that increased β means more factors interact with
cancer cell per minute. That could potentially lead to decreased total dosage or frequency of
administration. On the other hand decreasing β could even lead to cancer surviving in some
cases depending on the dosage which would mean that there needs to be a higher or a more
frequent dosage in order to kill cancer. We believe that as long as we are in the parameter
regime where the ODE provides a sound approximation of the ABM, β does not aﬀect the
pattern of optimal dosage as evident by the distributions found for half and double the
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original value of β used. That leads to the conclusion that the pattern is mainly dependent
on the growth rates and hierarchy of the cancer cells.
The SDE model provides a more realistic alternative and we observed that it captures
the variation observed in the ABM for the speciﬁc parameter values. Despite the fact that
there was some noticeable variation in the healthy cell population, noise had little eﬀect to
the malignant populations which are the important ones for the optimization and sensitivity
analysis performed. Due to that very narrow variation in these populations we are conﬁdent
that a mean ﬁeld approach (ODE) provides a sound approximation and would give very
similar results to the SDE, on top of making numerical simulations less challenging.
Dosage distribution optimization was conducted via exhaustive search of the possible
dose combinations for a particular total dosage. This brute force approach to optimizing the
dosage was selected due to the fact that we only have four diﬀerent cases so the number of
combination for a speciﬁc total dosage is not very high. In addition to determining optimum
distribution, which can potentially be used to reduce either ToCE or amount of dosage, there
can be further exploration in order to ﬁnd both the best timing for administration of each
of the four doses as well as the best dosing scheme. A dosing scheme would mean a varying
dose size which would be a function of the respective cancer size rather than a constant
dosage size as in this paper. This additional exploration was not conducted here as the main
aim of the paper was to show that a connection between agent-based and continuum models
can be achieved in the cancer-related clinical setting.
5 Conclusion
Based on experimental evidence and a previously developed agent-based model we built a
very similar model which was used as our basis for attempting a connection between discrete
and continuous models. To this end we formulated two continuous models, one ODE and
one SDE, in order to capture the behaviour of the ABM for speciﬁc, experimentally derived
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parameters. The match between both models and the ABM was close both qualitatively
and quantitatively which allowed for an extension of the ODE so that it can be used for
more complex analysis, speciﬁcally optimization and sensitivity analysis. Through dosage
optimization the pattern of optimum distribution for the four doses was found which shows
signiﬁcant gains in comparison to equal distribution of the four doses. Finally, a sensitivity
analysis was conducted for a patient missing some doses which clearly demonstrated that
the position of the dosage in the course of therapy is important. Future work can move in
two directions, either towards the development of a new type of model (PDE) in order to
capture the ABM better or towards more systematic optimization of doses using the already
derived ODE. The latter is possible as we already mentioned that for a speciﬁc parameter
space (when cancer dies out) the two types of models have a close ﬁt. Further optimization
would be necessary in order to ﬁnd not only the right timing for administration of a certain
dosage but also a varying-size scheme which could signiﬁcantly reduce the overall amount
and yet keep the ToCE to an acceptable range.
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Appendix
Comparison of original ABM to the one developed in this paper
Here we present two plots, ﬁgure 11 and ﬁgure 12, similar to the ones found in Fig.31 for the
hypothetical case of 100% ﬁtness. The ﬁrst ﬁgure is for a constant dosage of 1000 factors for
all 4 doses and a frequency of 8 hours whereas the second in for a dosage of 250 factors for all
4 doses and the same frequency. The time unit here is minutes whereas in the original plot it
is days more speciﬁcally the plots range from 0 to 1.75 and 0 to 3.75 days which correspond
to 0 to 1800 and 0 to 5400 respectively in our case.
Langevin representation of reaction systems
According to Gillespie,8 in a system of chemical reactions we can use the Master equation to
describe its evolution. The Master Equation is an ODE describing the probabilistic change
29
Figure 11: Simulation results for the hypothetical case of 100% factor ﬁtness. For the case
where Fp = Fm = Fg = Fd = M(0) = 1000.
of the state of the system. If two conditions are satisﬁed then according to that paper the
Master Equation can be approximated by the Langevin equation, an SDE describing the
evolution of the reactants population due to deterministic and stochastic events. The two
conditions are:
(A) We require that there exists an inﬁnitesimal interval dt, such that the change in the
propensity. i.e,
αj(Xt′) = αj(Xt),
where t′ = t+ dt and αj(X) = cjhj(X). Here h(X) is equal to the product of the concentra-
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Figure 12: Simulation results for the hypothetical case of 100% factor ﬁtness. For the case
where Fp = Fm = Fg = Fd = 250.
tion of the reactants in bimolecular reactions or equal to the concentration of one reactant
in monomolecular reactions.
(B) We require that this dt is large enough that the expected number of interactions is
large.
These two conditions might seem contrasting but in the case of large populations they
are both satisﬁed as (i) more than one reaction will occur in dt and (ii) the change of the
populations in that interval will be insigniﬁcant compared to the total population and hence
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the propensity will be almost constant.
If these two conditions are satisﬁed then it can be shown that a random variableK(X(t), t)
can become a statistically independent Poisson variable P (a(X(t)), t) and then a normal ran-
dom variable N(a(X(t))dt, a(X(t))dt). Following that one can use the linear combination
theorem for normal random variables,
N(m,σ2) = m+ σ ∗N(0, 1),
to write the normal random variable in the following form:
a(X(t))dt+ (a(X(t))dt)1/2.
Using the procedure explained in8 one can ﬁnd the Langevin equation satisfying the
system and that equation will be a good approximation of the Master equation. Furthermore,
one can ﬁnd the Fokker-Plank equation but here we concentrate on the Langevin. The general












Here, νj,i describes the change in the population Xi due to reaction j and Γj is Gaussian
white noise. The above formula was formulated by its discretized version which we use to
simulate the model in Mathematica. The discretized version, which can be recognized as the
Euler-Maruyama method, is:










N(0,1) is a random number of a normal distribution with mean zero and unit variance.
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.1 Application to present ABM
Let us consider our cells and factors reaction model. We have the following reactions:
1. ﬁve reproducitons of the form X → 2X with rates gp, gm, go, gd, gh respectively
2. four productions ∅ → Fi with rate D
3. four interactions of the form X + Fx → ∅ with rate β.
So in total there are thirteen reactions. That gives the following vector and matrix for α
and ν:
α = {gpP, gmM, goO, gdD, ghH,D,D,D,D, βPFp, βMFm, βOFo, βDFd},
ν =

1 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0
0 0 0 1 0 0 0 0 0
0 0 0 0 1 0 0 0 0
1 0 0 0 0 1 0 0 0
1 0 0 0 0 0 1 0 0
1 0 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 1
−1 1 0 0 0 −1 0 0 0
0 −1 1 0 0 0 −1 0 0
0 0 −1 1 0 0 0 −1 0




We can then formulate the Langevin equations for the populations using the formula men-
tioned above.
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